Search clinical trials for: AZD4041

Total 108 results

AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca
Altasciences Company Inc.

Completed

A Safety Study of AZD4041 in Healthy Participants

Opioid Use Disorder (OUD)

Canada
AstraZeneca

Terminated

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Cardiovascular Disease
Samsung Medical Center

Withdrawn

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)

Solid Tumor

Korea, Republic of
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
AstraZeneca

Completed

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

United Kingdom
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Withdrawn

Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043 (AZD3043)

Pharmacokinetics | Sedation | Tolerability | Safety
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Healthy Volunteers

United States
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
AstraZeneca

Completed

AZD Single Ascending Dose Study In Healthy Japanese Subjects (JSAD)

Healthy

United Kingdom
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
Massachusetts General Hospital
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Meningioma

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
Samsung Medical Center
AstraZeneca

Terminated

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
AstraZeneca

Completed

A Study in Participants With Non-cirrhotic NASH With Fibrosis (COSMOS)

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Denmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca
Parexel

Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Cardiovascular Disease

United States
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
AstraZeneca

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 (AZD4451 SAD)

Bipolar Disorder

United States
AstraZeneca

Completed

Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers (SAD)

Healthy Volunteers

Sweden
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
Samsung Medical Center

Withdrawn

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)

Solid Tumor

Korea, Republic of
AstraZeneca

Completed

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
AstraZeneca
Quotient Sciences

Active, not recruiting

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Asthma

United Kingdom
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
AstraZeneca

Recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

Denmark, United States, United Kingdom, Argentina, Vietnam, Brazil, Malaysia, France, Germany, Spain, Taiwan, Thailand, Bulgaria, Philippines, South Africa, Sweden
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (TAX-TORC)

Advanced Cancer

United Kingdom
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
Canadian Cancer Trials Group
AstraZeneca

Completed

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Glioblastoma Multiforme

Canada
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
University of Leeds

Completed

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)

Diabetes Mellitus, Type 2

United Kingdom

3

Subscribe